Bright Minds Biosciences
Bright Minds Biosciences
DRUG
NASDAQ
35.71
USD
-1.49%
About
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain.
Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.8K |
| Three Month Average Volume | 16.9K |
| High Low | |
| Fifty-Two Week High | 2.13629 USD |
| Fifty-Two Week Low | 0.89766 USD |
| Fifty-Two Week High Date | 02 Feb 2024 |
| Fifty-Two Week Low Date | 30 Apr 2024 |
| Price and Volume | |
| Current Price | 0.90462 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -14.64% |
| Thirteen Week Relative Price Change | -24.39% |
| Twenty-Six Week Relative Price Change | -50.82% |
| Fifty-Two Week Relative Price Change | -60.35% |
| Year-to-Date Relative Price Change | -44.95% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -20.73% |
| Twenty-Six Week Price Change | -46.72% |
| Five Day Price Change | -12.75% |
| Fifty-Two Week Price Change | -54.39% |
| Year-to-Date Price Change | -38.68% |
| Month-to-Date Price Change | -10.34% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.21722 USD |
| Book Value Per Share (Most Recent Quarter) | 0.9508 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.21722 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.9508 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.58664 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -69585.83474 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -69585.83474 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.37912 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.64193 USD |
| Normalized (Last Fiscal Year) | -1.37912 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.37912 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.6405 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.37912 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.64193 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.24485 USD |
| Cash Per Share (Most Recent Quarter) | 0.96498 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.36557 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.57972 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.43005 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 112.79% |
| EPS Change (Trailing Twelve Months) | 65.15% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -6,176,220 |
| Net Debt (Last Fiscal Year) | -6,674,440 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 24 |
| Current Ratio (Most Recent Quarter) | 35 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -7,024,270 |
| Free Cash Flow (Trailing Twelve Months) | -2,584,550 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1,325 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -77.74% |
| Return on Assets (Trailing Twelve Months) | -48.26% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -86.02% |
| Return on Equity (Trailing Twelve Months) | -51.45% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -85.66% |
| Return on Investment (Trailing Twelve Months) | -51.40% |
| Return on Investment (5 Year) | -99,999.99% |